Genta/Betamet/Clotrim Ear Oint

Verify with FDA CVM →

511 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
511
Total Reports
10
Deaths Reported
200.0%
Death Rate

Active Ingredients

Genta/Betamet/Clotrim Ear Oint

Administration Routes

Auricular (Otic)UnknownTopicalOralOphthalmicOtherSubcutaneous

Species Affected

Dog 403
Unknown 94
Cat 14

Most Affected Breeds

Unknown 96
Crossbred Canine/dog 79
Retriever - Labrador 43
Retriever - Golden 22
Terrier - Yorkshire 17
Shepherd Dog - German 17
Dog (unknown) 17
Boxer (German Boxer) 15
Pug 13
Chihuahua 13

Most Reported Reactions

Deafness 225
Partial deafness 47
Drug administration duration too long 41
Applicator, Abnormal 27
Product problem 25
Product Defect, General 22
Underdose 22
Drug dose administration interval too long 21
Containers, Leaking 19
Drug dose prescribing error 19
Lethargy (see also Central nervous system depression in 'Neurological') 18
Lack of efficacy - NOS 17

Outcome Breakdown

Recovered with Sequela
189 (45.3%)
Recovered/Normal
94 (22.5%)
Ongoing
71 (17.0%)
Outcome Unknown
53 (12.7%)
Euthanized
7 (1.7%)
Died
3 (0.7%)

Data Summary

Metric Value
Total adverse event reports 511
Reports involving death 10
Case-fatality rate (reported events) 200.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Genta/Betamet/Clotrim Ear Oint Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 511 adverse event reports referencing Genta/Betamet/Clotrim Ear Oint, including 10 reports in which the animal died — a 200.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Genta/Betamet/Clotrim Ear Oint. Reported administration routes include Auricular (Otic), Unknown, Topical, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Genta/Betamet/Clotrim Ear Oint reports are Dog (403 reports), Unknown (94 reports), Cat (14 reports), with Dog accounting for the largest share. Within those species, Unknown (96), Crossbred Canine/dog (79), Retriever - Labrador (43) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Genta/Betamet/Clotrim Ear Oint are Deafness (225), Partial deafness (47), Drug administration duration too long (41), Applicator, Abnormal (27). Of the 417 reports with a coded outcome, Recovered with Sequela is the leading category at 45.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Genta/Betamet/Clotrim Ear Oint.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial